Bard Associates Inc. Sells 1,200 Shares of Harrow, Inc. (NASDAQ:HROW)

Bard Associates Inc. decreased its position in shares of Harrow, Inc. (NASDAQ:HROW) by 2.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,500 shares of the company’s stock after selling 1,200 shares during the quarter. Bard Associates Inc. owned approximately 0.16% of Harrow worth $1,929,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in Harrow by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company’s stock worth $8,563,000 after acquiring an additional 3,589 shares in the last quarter. Versor Investments LP purchased a new stake in shares of Harrow in the 4th quarter worth approximately $305,000. Bank of New York Mellon Corp lifted its position in shares of Harrow by 8.4% in the 4th quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company’s stock worth $2,900,000 after purchasing an additional 6,690 shares during the period. Bleakley Financial Group LLC boosted its stake in shares of Harrow by 63.1% during the fourth quarter. Bleakley Financial Group LLC now owns 8,770 shares of the company’s stock valued at $294,000 after purchasing an additional 3,394 shares in the last quarter. Finally, Calamos Advisors LLC increased its holdings in Harrow by 35.2% during the fourth quarter. Calamos Advisors LLC now owns 11,913 shares of the company’s stock valued at $400,000 after buying an additional 3,103 shares during the period. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Analyst Ratings Changes

HROW has been the topic of several recent research reports. HC Wainwright assumed coverage on Harrow in a research report on Thursday, February 6th. They set a “buy” rating and a $57.00 target price on the stock. B. Riley dropped their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th.

Harrow Price Performance

NASDAQ HROW opened at $25.63 on Tuesday. The firm’s fifty day simple moving average is $32.35 and its two-hundred day simple moving average is $39.93. The firm has a market capitalization of $912.81 million, a P/E ratio of -27.27 and a beta of 0.69. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 12-month low of $9.30 and a 12-month high of $59.23.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.